Ashkon Software



NWBOW - Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. logo Northwest Biotherapeutics, Inc., trading under the ticker symbol NWBO, was a biotechnology company that developed immunotherapy treatments for cancer. The company was headquartered in Bethesda, Maryland.

Northwest Biotherapeutics' lead product candidate was DCVax, a personalized immune therapy that was being developed for the treatment of various types of cancer, including brain cancer and ovarian cancer. The company also had other product candidates in its pipeline that were being developed for the treatment of various cancers.

In 2019, Northwest Biotherapeutics filed for bankruptcy, and the company was delisted from the NASDAQ stock exchange.

Prior to its bankruptcy, as of its most recent financial filings, Northwest Biotherapeutics had a market capitalization of approximately $32 million and employed over 50 professionals across its various operations worldwide. The company faced challenges in securing funding for its research and development activities and in successfully completing clinical trials for its product candidates.

Investors who held NWBO stock may have lost their investment as a result of the bankruptcy. Investors who are interested in the biotechnology industry may want to research other publicly traded companies in the sector, evaluate their financial performance, competitive position, and growth prospects. The biotechnology industry is highly competitive, and the success of a company's research and development activities is




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer